-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bone marrow growth syndrome is a cancer caused by blood cells that form in the bone marrow that are dysfunctional or dysfunctional.
has not been approved by the FDA in 14 years.
low-risk MDS patients had an average survival of 6 years, and high-risk MDS patients had an average survival of about 18 months.
CD47 is a "don't eat me" signal expressed on the cell surface, preventing normal cells from being swallowed by macrophages by binding to THEP alpha lipolys on the surface of macrophages.
in many cancer types, tumor cells also prevent them from being swallowed by macrophages by expressing CD47.
Magolimab is an anti-CD47 monoclonal antibody acquired by Gilead Sciences through the acquisition of Forty Seven.
it is designed to disrupt the "Don't Eat Me" signal by binding to CD47, interfering with the recognition of CD47 by sirP alpha subjects on macrophages.
FDA has granted magolimab fast-track status for the treatment of MDS, acute myeloid leukemia, diffuse large B-cell lymphoma and fable lymphoma.
mechanism of the anti-CD47 antibody (Photo: Forty Seven)This breakthrough therapy was awarded based on the positive results of an ongoing Phase 1b study.
, released at the 2020 European Hematological Association conference, showed that among 33 patients with assessable efficacy, magrolimab and azatide combined therapy achieved an objective remission rate of 91 per cent and 42 per cent achieved complete remission (CR).
Magolimab is currently being evaluated in a randomized double-blind, placebo-controlled Phase 3 clinical trial ENHANCE, in association with azatides to treat patients with primary treatment of high-risk MDS.
references: sgiad's Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA File Therapy Designation for Treatment of Myelodysplastic Syndrome. Retrieved September 15, 2020, from.